Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

被引：0
|
作者：
Selmi, Carlo [1 ]
Salaffi, Fausto [2 ]
Aydin, Sibel [3 ]
Soriano, Enrique [4 ,5 ]
Rampakakis, Emmanouil [6 ]
Sharaf, Mohamed [7 ]
Zimmermann, Miriam [8 ]
Lavie, Frederic [9 ]
Nash, Peter [10 ]
Mease, Philip J. [11 ,12 ]
机构：
[1] Humanitas Univ, Humanitas Res Hosp, Rheumatol & Clin Immunol, Internal Med, Rozzano, Italy
[2] Polytech Univ Marche, Carlo Urbani Hosp, Dept Clin & Mol Sci, Ancona, Italy
[3] Ottawa Hosp Riverside Campus, Dept Med, Ottawa, ON, Canada
[4] Hosp Italiano Buenos Aires, Internal Med Serv, Rheumatol Sect, Buenos Aires, DF, Argentina
[5] Univ Inst Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[6] McGill Univ, Dept Pediat, Sci Affairs, JSS Med Res, Montreal, PQ, Canada
[7] Janssen MEA, Immunol, Dubai, U Arab Emirates
[8] Janssen Med Affairs LLC, Immunol, Zug, Switzerland
[9] Johnson & Johnson, Janssen Pharmaceut Co, Paris, France
[10] Griffith Univ, Sch Med, Brisbane, Qld, Australia
[11] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[12] Univ Washington, Sch Med, Seattle, WA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1429
引用
收藏
页码：2809 / 2811
页数：3
相关论文
共 50 条
  • [1] Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab
    Nash, Peter
    McInnes, Iain
    Ritchlin, Christopher T.
    Tam, Lai-Shan
    Soriano, Enrique
    Starr, Michael
    Rampakakis, Emmanouil
    Lavie, Frederic
    Shawi, May
    Baraliakos, Xenofon
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2785 - 2787
  • [2] Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
    Felten, Renaud
    Widawski, Laura
    Spielman, Lionel
    Gottenberg, Jacques-Eric
    Duret, Pierre-Marie
    Rampakakis, Emmanouil
    Sharaf, Mohamed
    Constantin, Caren
    Campana, Vincenza
    Messer, Laurent
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4429 - 4432
  • [3] Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
    Coates, Laura C.
    Gossec, Laure
    Zimmermann, Miriam
    Shawi, May
    Rampakakis, Emmanouil
    Shiff, Natalie J.
    Kollmeier, Alexa P.
    Xu, Xie L.
    Nash, Peter
    Mease, Philip J.
    Helliwell, Philip S.
    RMD OPEN, 2024, 10 (01):
  • [4] IMPACT OF PSORIATIC ARTHRITIS MANIFESTATIONS ON PERCEPTION OF PAIN IMPROVEMENT: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDIES WITH GUSELKUMAB
    Nash, P.
    Mcinnes, I.
    Ritchlin, C. T.
    Tam, L. S.
    Soriano, E.
    Starr, M.
    Rampakakis, E.
    Lavie, F.
    Shawi, M.
    Baraliakos, X.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1771 - 1772
  • [5] Efficacy of guselkumab in bionaive psoriatic arthritis patients with severe disease activity: post hoc analysis of Phase 3, randomized, double-blind, placebo-controlled study
    Ritchlin, Christopher T.
    Lubrano, Ennio
    Chimenti, Maria Sole
    Leibowitz, Evan
    Sharaf, Mohamed
    Rampakakis, Emmanouil
    Chakravarty, Soumya
    Nantel, Francois
    Lavie, Frederic
    Deodhar, Atul
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [6] Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Ritchlin, Christopher
    Lubrano, Ennio
    Chimenti, Maria Sole
    Leibowitz, Evan
    Sharaf, Mohamed
    Adelakun, Oyediran
    Rampakakis, Emmanouil
    Nantel, Francois
    Lavie, Frederic
    Deodhar, Atul
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2999 - 3001
  • [7] Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
    Eder, Lihi
    Selmi, Carlo
    Mease, Philip
    Ogdie, Alexis
    Nantel, Francois
    Lavie, Frederic
    Sharaf, Mohamed
    Adelakun, Oyediran
    Rampakakis, Emmanouil
    Vegas, Laura Pina
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4720 - 4722
  • [8] Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Kay, Jonathan
    Fleischmann, Roy
    Keystone, Edward C.
    Hsia, Elizabeth C.
    Goldstein, Neil
    Hsu, Benjamin
    Zhou, Yiying
    Braun, Juergen
    Kavanaugh, Arthur
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S198 - S199
  • [9] GOLIMUMAB 5-YEAR SAFETY: AN ANALYSIS OF POOLED DATA FROM THE LONG TERM EXTENSIONS OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS
    Kay, J.
    Fleischmann, R.
    Keystone, E.
    Hsia, E. C.
    Goldstein, N.
    Hsu, B.
    Zhou, Y.
    Braun, J.
    Kavanaugh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 241 - 242
  • [10] Disability Severity Category Shift With Fremanezumab Treatment: Pooled Results of 3 Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies
    Nagy, A. J.
    Cohen, J. M.
    Ning, X.
    Ramirez-Campos, V
    Janka, L.
    McAllister, P.
    HEADACHE, 2020, 60 : 11 - 11
12345